A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

Affiliations

• ¹ Department of Haematology, Oxford University Hospital, NHS Trust, Oxford, United Kingdom. Karthik.ramasamy@ndcls.ox.ac.uk.
• ² Winship Cancer Institute, Emory University, Atlanta, GA, USA.
• ³ University of Melbourne, St. Vincent's Hospital, Fitzroy, VIC, Australia.
• ⁴ City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
• ⁵ University College London Hospitals, NHS Foundation Trust, London, United Kingdom.
• ⁶ Stanford University Cancer Center, Stanford, CA, USA.
• ⁷ Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
• ⁸ Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Newton, MA, USA.
• ⁹ Department of Medicine, Duke Univ. Medical Center, Durham, NC, USA.
• ¹⁰ Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.
• ¹¹ Department of Clinical Haematology, Prince of Wales Hospital, Sydney, NSW, Australia.
• ¹² Roche Pharma Research and Early Development, New York, NY, USA.
• ¹³ Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
• ¹⁴ Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
• ¹⁵ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
• ¹⁶ The Multiple Myeloma Research Foundation, Norwalk, CT, USA.